The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.» Read More
Markets wavered on Friday after a better-than-expected reading on consumer sentiment. How should investors position their portfolios going forward? Bob Auer, portfolio manager at Auer Growth Fund, Jerry Castellini, president and CIO of CastleArk Management, and Mark Freeman, portfolio manager at WHG Funds, discussed their insights.
Cubist Pharmaceuticals is rebounding from a three-month low, and some bulls are looking for a sharp surge higher amid buyout rumors.
Following are the day’s biggest winners and losers. Find out why shares of American Eagle and Nokia popped while Sun Microsystems and McGraw-Hill dropped.
With the market trending higher and a critical jobs report due Friday morning, how should you be positioned?
With stocks slowing climbing back up, should investors start putting cash to work again or should they continue to sit back and wait for a pullback? Portfolio managers Robert Loest of Integrity, Growth & Income and Bob Auer of Auer Growth Fund shared their opposing market outlooks.
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Stocks rose on Friday for the 4th day in a row, with the Dow closing out its best four-week winning streak since 1933.
Cubist Pharmaceuticals is up more than 12 percent today with heavy options activity amid rumors that the company will be bought by Swiss drug giant Novartis.
The market suffered steep losses in 2008, but some companies defied the odds and ended the year with impressive gains.
Cramer makes the call on viewers' favorite stocks.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
The buzz on the street on this morning is "earnings", says Scott Fullman, director of investment strategy for IA Englander & Co.
Time to put back Jonathan Tucker's photo in the blog post as the actor has pushed out poker champion Chris Moneymaker from the top spot in Trading With The Stars. Jonathan is now followed by fellow actor Stephen Collins in 2nd. Moneymaker lost on Cubist Pharma which fell 7.46% Thursday. It's a close race between the top 3, with only....
Good morning. Serge Amelyan continues to hold the top position on the overall leaderboard, while the upset occurs as Parker Robinson falls to third, displaced by Vitaliy Khizder who moves into 2nd. As we said Thursday, Serge is the first contestant to break the $3M mark with a total portfolio value of $3,275,721.77 up $39,498.72 from Wednesday's total on the sale of...
It was a volatile day for the celebs. Champion poker player Chris Moneymaker holds onto the first spot despite his $90K loss on Syntel but actor Jonathan Tucker takes over the #2 spot. Meanwhile, Willie Garson falls into 4th, allowing Stephen Collins to gain 3rd place. Johnny Bench falls from 6th to 8th. One of the stocks for Chris M., CBST, is also a favorite of Parker Robinson in our non-celeb trading. Both are "banking" on it paying off.
Good morning all. Serge Amelyan maintains his lead for the second day running, and Parker Robinson holds 2nd place--as both gain substantially with the top trade of the day on Linear Technology. It was was up 12.20% Wednesday on strong earnings. AND Serge is the first contestant to break the $3M mark with a total portfolio value of $3,236,223.05 up $351,671.04 from Tuesday's total on the sale of Linear Technology.
Hey folks--we have guest blogger Jeff Mishlove's contest picks for the day. Let's get right to his comments: Now that the Tuesday results are in, I see that my top recommendation for Monday had a significant price gain. That was Adtran, Inc., which rose 6.16%. This stock had a lot going for it: it was favored by hedge funds and professional investors; it was approaching its 52-week high; a significant amount of stock was controlled by short sellers..